Organon & Co (OGN)
Operating profit margin
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
---|---|---|---|---|
Operating income | US$ in thousands | -922,000 | -412,000 | -83,000 |
Revenue | US$ in thousands | 6,263,000 | 6,174,000 | 6,304,000 |
Operating profit margin | -14.72% | -6.67% | -1.32% |
December 31, 2023 calculation
Operating profit margin = Operating income ÷ Revenue
= $-922,000K ÷ $6,263,000K
= -14.72%
The operating profit margin of Organon & Co. has shown a decreasing trend over the past five years. The margin was 21.19% at the end of 2023, down from 27.62% in 2022 and 28.73% in 2021. This decline in operating profit margin indicates that the company's profitability from core operations has been weakening. Further analysis would be required to determine the specific factors contributing to this downward trend and to assess the overall financial health and performance of Organon & Co.
Peer comparison
Dec 31, 2023
Company name
Symbol
Operating profit margin
Organon & Co
OGN
-14.72%
Abbott Laboratories
ABT
16.43%
AbbVie Inc
ABBV
23.49%
Alkermes Plc
ALKS
25.25%
Amphastar P
AMPH
30.57%
ANI Pharmaceuticals Inc
ANIP
10.34%
Arcus Biosciences Inc
RCUS
-290.60%
Biomarin Pharmaceutical Inc
BMRN
6.66%
Bristol-Myers Squibb Company
BMY
-20.64%
Catalent Inc
CTLT
-17.10%
Catalyst Pharmaceuticals Inc
CPRX
21.80%